News

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.
Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.
News about Vertex Pharmaceuticals Inc., including commentary and archival articles published in The New York Times.
Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...
Vertex Pharmaceuticals Inc. said more than 20,000 prescriptions have been dispensed for its new non-addictive painkiller, a sign that the drug is gaining some early traction as it attempts to ...
It's the first new class of pain treatment approved in more than 20 years, Vertex says. Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug ...
If you have non-public information about Vertex Pharmaceuticals Inc., you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange ...
Vertex Pharmaceuticals Inc. said it's stopping work on two potential drugs for a genetic lung disorder, but is now predicting a better-than-expected 2024 product revenue. The Boston drug developer ...
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) reported a profit for first quarter that decreased from the same period last year and missed the Street estimates.
Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc. presented to its investors.
Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall.